SCHEMBL644275

SCHEMBL644275

CN(C)C(=O)c1ncc(Br)cn1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.39
SMN1; SMN2 Q16637 4/20 0.36
KDM4E B2RXH2 3/20 0.36
HTT P42858 1/20 0.36
LMNA P02545 1/20 0.35
KMT2A Q03164 3/20 0.33
MAP4K1 Q92918 2/20 0.33
MEN1 O00255 1/20 0.33
GCK P35557 2/20 0.33
RAB9A P51151 2/20 0.33
NPC1 O15118 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.32
ALOX15 P16050 1/20 0.32
HSD17B10 Q99714 1/20 0.32
OPRK1 P41145 1/20 0.32
PARP1 P09874 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2877835 0.80 MEN1 (0.41) ALDH1A1KDM4EKMT2AMEN1RAB9A
SCHEMBL1721213 0.80 GBA1 (0.38) ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1
SCHEMBL13388128 0.80 GRM5 (0.49) ALDH1A1SMN1; SMN2KDM4EHTT
SCHEMBL15780518 0.80 APLNR (0.41) ALDH1A1SMN1; SMN2KDM4ELMNAKMT2A
SCHEMBL24655830 0.78 MAP4K1 (0.40) ALDH1A1SMN1; SMN2KDM4EKMT2AMAP4K1
SCHEMBL22048023 0.78 ALDH1A1 (0.33) ALDH1A1SMN1; SMN2KDM4EKMT2AMAP4K1
SCHEMBL5011310 0.78 HCRTR1 (0.44) ALDH1A1SMN1; SMN2LMNARAB9ANPC1
SCHEMBL15142128 0.75 GCK (0.39) ALDH1A1SMN1; SMN2KDM4EGCKHPGD
SCHEMBL23021755 0.75 FAAH (0.35) ALDH1A1SMN1; SMN2KDM4EKMT2AMAP4K1
SCHEMBL31126503 0.75 GRM5 (0.33) ALDH1A1SMN1; SMN2KDM4EKMT2AMAP4K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4683672-A1 BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF Beone Medicines I GmbH (CH) 2026-01-28 EP disclosed
US-20260014147-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2026-01-15 US disclosed
US-20260007761-A1 Bioactive Conjugate, Preparation Method Therefor and Use Thereof BEONE MEDICINES I GMBH (CH) 2026-01-08 US disclosed
US-20260001893-A1 SMALL MOLECULE MODULATORS OF STAT6 GILEAD SCIENCES INC (US) 2026-01-01 US disclosed
US-20250340551-A1 SMALL MOLECULE MODULATORS OF STAT6 GILEAD SCIENCES INC (US) 2025-11-06 US disclosed
US-20250325677-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-23 US disclosed
US-20250320206-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 US disclosed
US-20250320205-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 US disclosed
WO-2024194851-A1 BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF BEIGENE SWITZERLAND GMBH (CH) 2024-09-26 WO disclosed
EP-2463283-B1 Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases PFIZER PROD INC (US) 2014-06-11 EP disclosed
US-20100137322-A1 NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN ASTRAZENECA AB (SE) 2010-06-03 US disclosed
EP-2010520-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES Pfizer Products Incorporated (US) 2009-01-07 EP disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS PFIZER INC. 2008-11-13 US disclosed
EP-1891069-A1 2-PHENYL SUBSTITUTED IMIDAZOL [4,5B]PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS AstraZeneca AB (SE) 2008-02-27 EP disclosed
WO-2007122482-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PRODUCTS INC. (US) 2007-11-01 WO disclosed
WO-2007122482-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES PFIZER PRODUCTS INC. (US) 2007-11-01 WO disclosed
WO-2006125958-A1 2-PHENYL SUBSTITUTED IMIDAZOL [4 , 5B] PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS ASTRAZENECA AB (SE) 2006-11-30 WO disclosed
WO-2006125958-A1 2-PHENYL SUBSTITUTED IMIDAZOL [4 , 5B] PYRIDINE/ PYRAZINE AND PURINE DERIVATIVES AS GLUCOKINASE MODULATORS ASTRAZENECA AB (SE) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260007761-A1 Bioactive Conjugate, Preparation Method Therefor and Use Thereof IGLV6-57, BCR, INCENP ALDH1A1 2110/4885SMN1; SMN2 993/4885KDM4E 2548/4885
US-20100137322-A1 NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN OPRL1, OPRK1, OPRD1 ALDH1A1 854/4885SMN1; SMN2 619/4885KDM4E 3402/4885
US-20250325677-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 ALDH1A1 959/4885SMN1; SMN2 3259/4885KDM4E 167/4885
US-20250340551-A1 SMALL MOLECULE MODULATORS OF STAT6 STAT6, STAT1, STAT5B ALDH1A1 2050/4885SMN1; SMN2 4449/4885KDM4E 384/4885
US-20080280875-A1 FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS GCK, GCKR, HK1 ALDH1A1 1370/4885SMN1; SMN2 2653/4885KDM4E 1790/4885
US-20260001893-A1 SMALL MOLECULE MODULATORS OF STAT6 STAT6, NCOR1, NCOR2 ALDH1A1 3636/4885SMN1; SMN2 4101/4885KDM4E 1055/4885
US-20250320205-A1 STAT6 DEGRADERS STAT6, STAT1, STAT5B ALDH1A1 1225/4885SMN1; SMN2 3341/4885KDM4E 141/4885
US-20260014147-A1 STAT6 DEGRADERS STAT6, NCOR1, CBR1 ALDH1A1 1790/4885SMN1; SMN2 2651/4885KDM4E 739/4885
US-20250320206-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 ALDH1A1 959/4885SMN1; SMN2 3259/4885KDM4E 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.